Before heading on Easter break, the team discuss key takeaways from <a href='https://research.berenberg.com/report/B8F9381CA1B7DC224B4D38F929211F21'>DrugBank</a> and <a href='https://research.berenberg.com/report/E858A3BBDCBF5F0AFDB53A1C94A77B3A?cs=5&sb_userid=210316941&sb_eventid=544220'>Rebate Round-up</a> publications. Luisa and Kerry also touch on the latest clinical data readouts for AZN’s anti-IL-33 in COPD and the unfolding battle in rare genetic diseases (FSHD and DM1), between Novartis/Avidity, Sarepta and Dyne Therapeutics.

Before heading on Easter break, the team discuss key takeaways from DrugBank and Rebate Round-up publications. Luisa and Kerry also touch on the latest clinical data readouts for AZN’s anti-IL-33 in COPD and the unfolding battle in rare genetic diseases (FSHD and DM1), between Novartis/Avidity, Sarepta and Dyne Therapeutics.

Before heading on Easter break, the team discuss key takeaways from <a href="https://research.berenberg.com/report/B8F9381CA1B7DC224B4D38F929211F21" rel="noopener noreferrer">DrugBank</a> and <a href="https://research.berenberg.com/report/E858A3BBDCBF5F0AFDB53A1C94A77B3A?cs=5&amp;sb_userid=210316941&amp;sb_eventid=544220" rel="noopener noreferrer">Rebate Round-up</a>&nbsp;publications. Luisa and Kerry also touch on the latest clinical data readouts for AZN’s anti-IL-33 in COPD and the unfolding battle in rare genetic diseases (FSHD and DM1), between Novartis/Avidity, Sarepta and Dyne Therapeutics.&nbsp;

Episode 9

Welcome to “Over the Pill”, the Berenberg podcast where Kerry Holford &amp; Luisa Hector lift the curtain on the messy reality of analysing pharma share prices. With over 30 years of friendship, Kerry &amp; Luisa invite listeners into their regular debates on pharma strategy, drug pipeline prospects and commercial power.&nbsp;

Business

Welcome to “Over the Pill”, the Berenberg podcast where Kerry Holford & Luisa Hector lift the curtain on the messy reality of analysing pharma share prices. With over 30 years of friendship, Kerry & Luisa invite listeners into their regular debates on pharma strategy, drug pipeline prospects and commercial power. 

Share Episode 9

Sign up to save your podcasts

Episode 9

Episode 9